Characteristic | Number of events n (%) | Unadjusted | Fully adjusted* | ||
---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | ||
Mortality | |||||
 COPD | 127 (40.1) | 1.47 (1.14–1.88) | 0.002 | 1.20 (0.91–1.58) | 0.2 |
 Asthma | 30 (22.4) | 0.57 (0.38–0.87) | 0.008 | 0.98 (0.61–1.58) | 0.94 |
 Obstructive sleep apnea | 31 (49.2) | 2.04 (1.23–3.37) | 0.005 | 2.59 (1.46–4.58) | 0.001 |
 Pulmonary embolism | 13 (48.1) | 1.92 (0.90–4.12) | 0.09 | 1.86 (0.82–4.23) | 0.14 |
 Pulmonary hypertension | 4 (40) | 1.37 (0.38–4.87) | 0.62 | 1.09 (0.28–4.23) | 0.9 |
 Sarcoidosis | 1 (12.5) | 0.29 (0.04–2.38) | 0.28 | 0.39 (0.04–3.46) | 0.4 |
 Lung cancer | 4 (44.4) | 1.65 (0.44–6.15) | 0.45 | 1.24 (0.30–5.10) | 0.76 |
ICU admission | |||||
 COPD | 114 (36) | 1.26 (0.98–1.63) | 0.07 | 1.20 (0.92–1.58) | 0.18 |
 Asthma | 41 (30.6) | 0.95 (0.65–1.39) | 0.79 | 1.16 (0.77–1.74) | 0.47 |
 Obstructive sleep apnea | 32 (50.8) | 2.3 (1.39–3.80) | 0.001 | 1.95 (1.14–3.32) | 0.01 |
 Pulmonary embolism | 13 (48.1) | 2.30 (0.95–4.34) | 0.06 | 2.03 (0.93–4.44) | 0.08 |
 Pulmonary hypertension | 4 (40) | 1.44 (0.41–5.13) | 0.57 | 1.25 (0.34–4.62) | 0.74 |
 Sarcoidosis | 1 (12.5) | 0.31 (0.04–2.50) | 0.49 | 0.39 (0.05–3.21) | 0.38 |
 Lung cancer | 2 (22.2) | 0.62 (0.13–2.97) | 0.54 | 0.63 (0.12–3.28) | 0.58 |
Mechanical ventilation | |||||
 COPD | 99 (31.2) | 1.35 (1.04–1.76) | 0.02 | 1.28 (0.96–1.69) | 0.09 |
 Asthma | 33 (24.6) | 0.92 (0.61–1.38) | 0.68 | 1.08 (0.69–1.67) | 0.74 |
 Obstructive sleep apnea | 31 (49.2) | 2.85 (1.72–4.73) |  < 0.001 | 2.20 (1.28–3.78) | 0.004 |
 Pulmonary embolism | 9 (33.3) | 1.42 (0.63–3.18) | 0.39 | 1.45(0.63–3.34) | 0.39 |
 Pulmonary hypertension | 3 (30) | 1.21 (0.31–4.70) | 0.72 | 0.96 (0.23–3.92) | 0.95 |
 Sarcoidosis | 1 (12.5) | 0.40 (0.0–3.28) | 0.69 | 0.52 (0.06–4.30) | 0.54 |
 Lung cancer | 1 (11.1) | 0.35 (0.04–2.82) | 0.46 | 0.35 (0.04–3.00) | 0.34 |